Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells $70,251.08 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gary Patou sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE traded down $0.52 during midday trading on Monday, hitting $51.21. The company had a trading volume of 1,181,045 shares, compared to its average volume of 1,258,214. The company has a market cap of $4.95 billion, a price-to-earnings ratio of -10.90 and a beta of 0.62. The company has a fifty day moving average of $55.74 and a two-hundred day moving average of $48.68. Xenon Pharmaceuticals Inc. has a 12-month low of $30.00 and a 12-month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same quarter in the prior year, the company posted ($0.83) earnings per share. Research analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth $33,000. Blue Trust Inc. lifted its position in shares of Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 717 shares in the last quarter. Danske Bank A S acquired a new position in shares of Xenon Pharmaceuticals during the third quarter worth $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth $43,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in shares of Xenon Pharmaceuticals during the third quarter worth $39,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

XENE has been the subject of a number of recent analyst reports. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Royal Bank Of Canada boosted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, May 8th. HC Wainwright upped their price objective on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. JPMorgan Chase & Co. upped their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Finally, Guggenheim restated a “buy” rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $77.20.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.